This week's Fierce Biotech is brought to you by Hanson Wade.

Trouble viewing? Click here.

Hi E,

The Cannabinoid Derived Pharmaceuticals Summit is the world’s largest conference devoted exclusively to the production of CDPs for medical conditions using FDA/EMA approval pathways, with a focus on clinical trial design, commercialization, target biology and pharmacology, GMP-compliant product formulation, drug delivery, and managing the changing regulatory environment (particularly in light of new policies from the US government administration).

This is the only industry-led event that is solely dedicated to the advancement of cannabinoid pharmaceuticals that are developed with the same clinical rigor of any other regulated pharmaceutical.

Check out the Full Event Guide here to see the full speaker faculty and agenda.

What’s new this year?

• For the first time, large pharma will be represented on the agenda as Uwe Grether, Senior Principle Scientist at Roche presents a snapshot of their cannabinoid drug discovery program
• This year’s keynote address comes from GW Pharmaceuticals’ Alice Mead looking back at the last 23 years of growth and development: The Rise of GW: Keeping Patient Care as a Core Value
• Check out the brand-new agenda section titled Establishing a Robust Clinical Program to Achieve Approval.This new component features speakers from leading cannabinoid pharma companies such as Zelira Therapeutics, Incannex, CIITech, Oxford Cannabinoid Technologies and BOL Pharma, discussing the critical strategic decisions they made to gain an edge over the competition while finding new therapies to help patients with currently unmet clinical needs
• Meet new companies that are breaking into the cannabinoid field with novel technologies in our start-up carousel, where these companies will have a short presentation before being able to answer your questions
• An expanded Intellectual Property with greater depth and comprehensive coverage of how IP strategy can be improved and how effective prosecution/enforcement are important factors that influence success
• The 2021 conference will take place in person at the Aloft Boston Seaport District Boston this September 21-23

This year’s speaker faculty features a wide array of companies, with over 30 presentations from the following companies:

Avicanna | BOL Pharma | Roche | Cannabics Pharmaceuticals | Cannvalate | Canopy Growth | CB1 Capital | CIITECH | Cooley LLP | EMMAC Life Sciences | Golden Eagle Partners | Greenwich Biosciences | Ince & Co | InMed Pharmaceuticals | Intidyn | Intrinsic Capital Partners | Johns Hopkins School of Medicine | Khiron Life Sciences | Materia Medica Processing Srl | Materia Ventures | MGC Pharmaceuticals | Oxford Cannabinoid Technologies | Somme Therapeutics | Swinburne University | Tilray | University of Connecticut | University of Maryland | William Paterson University | Zelira Therapeutics

Download the Full Event Guide to see the full conference program planned to take place in Boston on September 21-23.

I sincerely hope you choose to join us at this year’s meeting.

Kind regards,

George

View our full Privacy Policy.
© 2021 Hanson Wade Ltd, 52 Grosvenor Gardens, London, SW1W 0AU, United Kingdom.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017